• About Us
    • Company Overview
    • Our History
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Advisors
  • Therapeutic Areas
    • Acute Myocarditis
    • Recurrent Pericarditis
    • Viral Infection and CVD
    • Heart Failure
  • Research
    • R&D Partners
    • Our Science
    • Resources
  • Pipeline
  • CardiolRX™
  • Investors
    • Events & Presentations
    • Press Releases
    • Analyst Coverage
    • Stock Information
    • Filings & Financials
    • Corporate Governance
    • Contact Us
  • Events & Presentations
  • Press Releases
  • Analyst Coverage
  • Stock Information
  • Filings & Financials
  • Corporate Governance
  • Investor Relations Contact
Investors

Press Releases

Press Release

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis

August 03, 2022

Press Release

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

June 29, 2022

Press Release

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT

June 27, 2022

Press Release

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

June 09, 2022

Press Release

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

May 19, 2022

Press Release

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis

May 17, 2022

Press Release

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

March 24, 2022

Press Release

Cardiol Therapeutics to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit

March 22, 2022

Press Release

Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors

March 15, 2022

Page 1 of 1012345...10...»Last »
  • About Us
  • Therapeutic Areas
  • Research
  • Pipeline
  • CardiolRX™
  • Investors
  • Contact

TSX:CRDL NASDAQ:CRDL

Sign up to receive the latest news from Cardiol Therapeutics

© 2022 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy